secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0000012208-22-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q1 revenue $700.1M (-3.7% YoY); core ex-COVID up 6.5%; non-GAAP EPS $4.94 vs $5.21
--------------------------------------------------------------------------------

- GAAP net loss $3.37B from Sartorius fair value change; non-GAAP net income $149.1M.
- Life Science segment sales $347.2M (-5.3% YoY); Clinical Diagnostics $351.8M (-1.9%).
- Full-year 2022 outlook: non-GAAP currency-neutral revenue growth ~1-2%; op margin ~19%.
- COVID-related revenue fell to ~$45M vs $94M in Q1 2021; core business grew 6.5% currency-neutral.
- Management notes macro risks: China lockdowns, Ukraine war, supply chain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000021/0000012208-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000021/bio-20220428.htm
  HTML page:      https://secwatch.observer/filing/0000012208-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer